Aurobindo Pharma has initiated recalling of nearly 5 lakh bottles of blood pressure lowering drugs in the US after the American health regulator found certain deviations from Current Good Manufacturing Practice (CGMP) regulations.
According to the latest Enforcement Report by the US Food and Drug Administration (USFDA), the company is recalling 1,62,301 bottles of Amlodipine and Valsartan Tablets, 3,12,095 bottles of Valsartan and Hydrochlorothiazide tablets and 20,604 bottles of Valsartan tablets in the US.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
